Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Investors Crow For Shares Of Zoetis As It Begins Trading On The NYSE

This article was originally published in The Pink Sheet Daily

Executive Summary

Zoetis makes its debut on the public stock exchange, garnering the highest priced IPO since Facebook began trading last year.

You may also be interested in...



Valeant/Ackman Going Whole Hog On Zoetis As Plan B For Allergan?

Valeant investment partner William Ackman takes a stake in animal health company Zoetis in what could be a move to change strategies as Allergan continues to oppose Valeant’s offer.

Lilly Feeds The Beast, But Is Novartis Animal Health Unit Worth The Price?

$5.4 billion deal boosts Lilly’s Elanco animal health business that adds both geographic scope and better product mix, but some investors snort at the high multiple.

Uptick In 4Q 2013 M&A Deal-Making Likely To Continue Into 2014, PwC Report Predicts

Earn-outs and other deal tools help bridge value gaps and share risk, enabling more deals to be finalized, report says. However, pharma is seeing increased M&A competition from biotechs looking to diversify and increase scale.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS075245

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel